14308 results for ""Pennsylvania+German"+ACS+study+'Socius'+open+access"

in 22.86 milliseconds.

• Hematology Research Unit Helsinki Data Access Committee

  Dac EGAC00001002444

• Data Access Committee for Niigata-NIG collaborative work

  Dac EGAC00001002469

• B cells in Multiple Sclerosis Data Access Committee

  Dac EGAC00001002476

• TNBC (COH_TNBC_RNAseq) - Data Access Committee at The Jackson laboratory

  Dac EGAC00001002518

• TNBC (UW_OvCa_RNASeq) - Data Access Committee at The Jackson laboratory

  Dac EGAC00001002524

• TNBC (UW_OvCa_WGS) - Data Access Committee at The Jackson laboratory

  Dac EGAC00001002544

• NPC genome-wide human SNP array data access commitee

  Dac EGAC00001002560

• Single-cell Multiomics Clonal Hematopoiesis Team Data Access Committee

  Dac EGAC00001002735

• Institute of Pathology LMU Munich Data Access Commitee

  Dac EGAC00001002931

• Institute of Pathology LMU Munich Data Access Commitee

  Dac EGAC00001002932

• Multiple myeloma long-term survivor data access commitee

  Dac EGAC00001003078

• Hospital del Mar Research Insitute Data Access Comitte

  Dac EGAC00001002512

• Kyoto Prefectural University of Medicine Data Access Commitee

  Dac EGAC00001003411

• TNBC (COH_WGS) - Data Access Committee at The Jackson laboratory

  Dac EGAC00001002574

• Experimental Therapeutics in Lymphoid Malignancies Data Access Commitee

  Dac EGAC00001003210

• HPV Virome Consortium Data Access Committee

  Dac EGAC00001000141

• Data access commitee at the Molecular Exercise Physiology group

  Dac EGAC00001002606

• APOBEC Breast Data Access Committee

  Sarat Chandarlapaty chandars@mskcc.org

  Dac EGAC50000000554

• UQCCR/QCMG brain metastasis sequence analysis Data Access Committee

  Dac EGAC00001000180

• Data Access Committee for Triple Negative Breast Cancer dataset

  Dac EGAC00001003584

• CINECA synthetic data.Please note: This study contains synthetic data (with cohort “participants” / ”subjects” marked with FAKE) has no identifiable data and cannot be used to make any inference about cohort data or results.

  Please note: This study contains synthetic data (with cohort “participants” / ”subjects” marked with FAKE) has no identifiable data and cannot be used to make any inference about cohort data or results. The purpose of this dataset is to aid development of technical implementations for cohort data discovery, harmonization, access, and federated analysis. In support of FAIRness in data sharing, this dataset is made freely available under the Creative Commons Licence (CC-BY). Please ensure this preamble is included with this dataset and that the CINECA project (funding: EC H2020 grant 825775) is acknowledged. For any questions please contact isuru@ebi.ac.uk or cthomas@ebi.ac.uk

  Study EGAS00001002472

• Bacterial Vaginosis, Cervical Immune Cells and HIV Susceptibility

  This was a cross-sectional study to characterize cervical immune cell composition and activation status in the presence versus absence of bacterial vaginosis (BV) using bulk messenger RNA sequencing (mRNA-Seq). Women enrolled in a longitudinal, open cohort study and engaged in a sex work in Mombasa, Kenya, were eligible. On the day of enrollment, participants self-collected vaginal swabs for generation of Gram-stained slide. The slides were scored from 0-10 using the method of Nugent and Hillier; in this system, women with scores of 0-3 are considered to have normal vaginal flora, those with scores of 4-6 are considered to have intermediate flora, and those with scores of 7-10 are considered to have BV. For this study, only women with normal flora (Nugent scores 0-3) or BV (Nugent scores 7-10) were eligible. Participants underwent speculum-assisted pelvic examination and collection of cervical biopsy specimens using Tischler forceps. Biopsies were placed immediately in ice cold medium and transferred to the laboratory where they were weighed and transferred to freezing medium (10% DMSO + fetal bovine serum) and cooled slowly overnight. Samples were shipped from Kenya to the United States in liquid nitrogen dry shippers, collagenase digested into single cell suspensions, and sorted on a FACS aria to enrich for a population of live, CD45+ cells. Sorted samples (N=17 with BV and N=13 without BV) were immediately lysed and processed using the Takara SMART-Seq v4 Ultra Low Input RNA Kit for sequencing. Library generation was completed using the manufacturer's instructions and sequencing performed on an Illumina NextSeq500 platform using Illumina NextSeq 500/550 High Output v2.5 (150 Cycles). The FASTQ files generated and BV status (N=9 with BV and N=12 without BV that passed quality control) of the donor sample will be available on dbGaP. We identified over 1000 differentially expressed genes between women with versus without BV at an adjusted p-value of <0.05 (listed under "gene names" below).

  Study phs002329

• T-bet+ CXCR3+ B cells drive hyperreactive B-T cell interactions in multiple sclerosis

  Data Access Committee means the following members of the Institute of Experimental Immunology, UZH, and investigators of the publication, to which the Data Access refers and who are responsible for making the data access decisions for the genotype and gene expression generated by UZH or respectively the epigenetic data, which had been generated at Karolinska Institute. Christian Münz, PhD; Co-Director of Institute of Experimental Immunology, University of Zurich Roland Martin, MD; Affiliated Group Leader (to Institute Münz) of Institute of Experimental Immunology Institute of Experimental Immunology Ivan Jelcic, PhD, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland Maja Jagodic, PhD, Department of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden

  Dac EGAC50000000464

• Single-cell RNA sequencing on 11,138 single T cells from 12 colon and rectal cancer (CRC) patients

  Deep single-cell RNA sequencing data for 11,138 T cells from tumour, adjacent normal tissue and peripheral blood of treatment-naive CRC patients. The DATA ACCESS AGREEMENT is provided at https://github.com/zhangyybio/single-T-cell-data-access. Applicants can request access to the data by directly downloading it or by sending an email to cancerpku@pku.edu.cn. The process that is used to approve an application includes verifying the institution, participants and research purposes of the application. In general this process will take about two weeks. In principal, any academic research institutions complying with the laws and bioethic regulation policies of China will be approved.

  Dataset EGAD00001003910

• Alpha1-Antitrypsin Deficiency Registry (AADR-BioLINCC)

  Data Access NOTE: Please refer to the &#8220;Authorized Access&#8221; section below for information about how access to the data from this accession differs from many other dbGaP accessions. Objectives: To characterize the clinical and laboratory course of patients with severe alpha 1-antitrypsin deficiency whether or not the patient is undergoing long-term augmentation therapy.Background: A hereditary disorder, patients with low serum levels of alpha-1-antitrypsin are at an increased risk for the early onset of emphysema. The only approved treatment for alpha-1-antitrypsin deficiency is augmentation therapy using a purified preparation of human alpha-1-antitryspin. Sample sizes for a randomized controlled clinical trial of augmentation therapy were determined to be infeasible; therefore, a multi-center registry was initiated in 1988 to explore the natural history of the disease and the relative efficacy of augmentation therapy in patients with a severe deficiency of alpha-1-antitrypsin.Participants: Eligible participants included individuals 18 years of age or greater for whom the Central Laboratory confirmed that the serum alpha 1-antitrypsin level is Conclusions: Participants receiving augmentation therapy had decreased mortality risk during follow-up. FEV1 decline among all participants did not differ by augmentation therapy; however, among participants with FEV1 35-49% predicted, FEV1 decline was significantly slower for participants on augmentation therapy than for those not receiving therapy. (Am J Respir Crit Care Med, 1998; 158:49-59)

  Study phs004187

• Whole Genome Sequencing Analysis in a Family of Discordant Twins With Non-Syndromic Microtia and Hemifacial Microsomia: Identification of Novel Candidate Genes and Variants

  This research is a non-NIH effort to discover the pathogenesis of non-syndromic microtia and to detect potential candidate genes. Microtia (OMIM 600674, 612290, 251800) is a spectrum of congenital anomalies and facial abnormalities, 90% of the cases followed by hearing loss. Two types of the disease are described in terms of connection to the affected syndromes: anomalies (syndromic) and only clinical manifestation (non-syndromic) associated with other symptoms. Though the exact pathogenesis of microtia remains unknown, pathogenic genes of majority of the microtia syndromic types have been identified. However, the genetic mutation of the non-syndromic microtia has not been confirmed. In this study, whole genome sequencing (WGS) was utilized to screen mutations in monozygotic discordant twins of congenital microtia-atresia and their family members. One of the twins, along with her grandfather, was discordant for microtia-atresia. By bioinformatic analysis of the WGS data from monozygotic twins with microtia and their non-microtia relatives, we proposed that among 28 identified potential genes, 4 of them (CNOT1, ODAD4, TBX15, and GIPC3) could be more responsible for non-syndromic microtia development and phenotypic features. Interested investigators may request to access the DNA genomic sequencing data of the study participants via dbGaP authorized access. In addition to raw genomic sequencing data, datasets of germline mutations and candidate gene mutations may also be available for investigators to request.

  Study phs003216

• Data Access Commitee for schizophrenia and control cases sequencing data

  Dac EGAC00001002810

• The data access committee for TIGIT in MCL with CART

  Dac EGAC00001003167

• Thirant, Peltier et al Data Access Commitee

  Dac EGAC00001001789

• Walter and Eliza Hall Institute Research Data Access Committee

  Dac EGAC00001003372

• Gencord Data Access Committee

  Dac EGAC00001000105

• Cancer Genomics Project RCC Data Access Committee

  Dac EGAC00001000109

• Data access committee for the head and neck project

  Dac EGAC00001000374

• Data Access Committee of National Institute of Genetics of Japan

  Dac EGAC00001000448

• North American Brain Expression Consortium (NABEC) Data Access Committee (DAC)

  Dac EGAC00001000560

• The NOWAC blood-breast cancer commitee data access agreement

  Dac EGAC00001000684

• Ovarian Granulosa Cell Tumor Sequencing Project Data Access Committee

  Dac EGAC00001000841

• Peking University BIOPIC Data Access Committee (PUBDAC)

  Dac EGAC00001000902

• Data Access Committee members for NETWork! project

  Dac EGAC00001000930

• Children's Cancer Therapy Development Institute Data Access Commitee

  Dac EGAC00001001160

• South Asia Rheumatic Heart Disease Genetics Network Data Access Committee

  Dac EGAC00001001161

• MTLE small RNA-sequencing and RNA-sequencing Data Access Committee

  Dac EGAC00001001427

• SEGA RNA-sequencing and small RNA-sequencing Data Access Commitee

  Dac EGAC00001001467

• StemNet Project Data Access Commitee

  Dac EGAC00001001472

• Tytgat Institute for Liver and Intestinal Research Data Access Committee

  Dac EGAC00001001483

• Tytgat Institute for Liver and Intestinal Research Data Access Committee

  Dac EGAC00001001485

• Egyptref Data Access Committee

  Dac EGAC00001001525

• Tytgat Institute for Liver and Intestinal Research Data Access Committee

  Dac EGAC00001001615

• Charite Berlin Paediatric Oncology Data Access Committee

  Dac EGAC00001001766

• Neutrophils infected with Leishmania donovani - Data Access Commitee

  Dac EGAC00001001874